Monday, June 26, 2006 12:03:46 PM
I agree that TRCA's PR is to let someone out of stock. p=0.48 or 48% or 48 every 100 is too big. This is not a good number to bragging about. However, it does provide good prospect for iPlex.
An additional analysis of hypoglycemic safety was also provided by Tercica. In 22 patients with severe Primary IGFD, up to four times daily blood glucose measurements were made before and for up to seven days after initiation of Increlex treatment. The results showed no statistically significant difference in the frequency of hypoglycemia observed before versus after the start of Increlex (7.0% and 8.8%, respectively; p=0.48).
An additional analysis of hypoglycemic safety was also provided by Tercica. In 22 patients with severe Primary IGFD, up to four times daily blood glucose measurements were made before and for up to seven days after initiation of Increlex treatment. The results showed no statistically significant difference in the frequency of hypoglycemia observed before versus after the start of Increlex (7.0% and 8.8%, respectively; p=0.48).
Recent INSM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:43:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/16/2026 08:17:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:41:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:01:21 PM
- Insmed Provides Clinical Update on Phase 2b CEDAR Study • PR Newswire (US) • 04/07/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:42:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:07:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 09:10:46 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/01/2026 08:03:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:02:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:01:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:13:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/30/2026 09:31:03 PM
- Insmed shares rise after UTHR trial data and Morgan Stanley upgrade • IH Market News • 03/30/2026 03:04:13 PM
- Insmed shares rise on positive results from ARIKAYCE Phase 3b study • IH Market News • 03/23/2026 02:34:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:00:30 AM
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease • PR Newswire (US) • 03/23/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:05:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 08:57:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:59:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:16:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:15:10 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:14:51 PM

